Resource

On-demand webinar: Next-generation sequencing: an emerging technique for measurable residual disease (MRD) detection in acute myeloid leukemia

Measurable residual disease (MRD) refers to the presence of malignant cells following treatment and is considered a strong predictor of relapse and overall survival in acute myeloid leukemia (AML). Assessment of MRD can be challenging due to the need for high sensitivity to detect small amounts of residual disease, the heterogeneity of myeloid neoplasms, and lack of standardization.

In this webinar, Dr. Jerald Radich, medical oncologist and researcher at Fred Hutchinson Cancer Center:

Shares the importance of MRD analysis in AML progression, prognosis, and therapy selection
Explains the challenges of traditional MRD testing methods and how next‑generation sequencing (NGS) is rapidly emerging as a powerful technique for comprehensive and highly sensitive detection
Discusses the latest research and medical guidelines and shares his perspective on the future of MRD detection with NGS

Speaker:

Jerald Radich, MD
Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Center

Please fill out the short form below to view this webinar.

(*Indicates a mandatory field)

First Name*

Last Name*

Institution*

Telephone

Email*

City*

Country/Region*

I would like to receive a quote or demonstration of Oncomine solutions for myeloid profiling and/or MRD detection